Uveal Melanoma Market

Market Overview:

The 7 major uveal melanoma markets reached a value of US$ 980 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,550 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The uveal melanoma market has been comprehensively analyzed in IMARC's new report titled "Uveal Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Uveal melanoma refers to a rare type of cancer that develops in the melanin-producing cells of the uveal tract of the eye. The uvea is the central layer of the eye's wall, which includes the iris, choroid, and ciliary body. The most common symptoms associated with the ailment are blurred vision, irritation, pain, a reduction in the total field of vision, redness, bulging or displacement of the eye, a perception of flashes of light in the eye, double vision, etc. Individuals suffering from this condition may also experience a change in the shape of the pupil and metamorphopsia, a visual distortion in which a person sees straight lines as wavy and sections of the grid as blank. The diagnosis of uveal melanoma typically involves a comprehensive eye examination by an ophthalmologist, who will examine the eye using a specialized microscope called a slit lamp. Various imaging tests, such as ultrasound, optical coherence tomography (OCT), fluorescein angiography, etc., are also utilized to evaluate the size and location of the tumor and to determine whether it has spread to other parts of the eye or surrounding tissues. Additionally, a biopsy may be performed to confirm the diagnosis of uveal melanoma and identify the specific characteristics of the tumor.

The rising cases of genetic conditions, which cause abnormalities in the DNA and uncontrollable growth of unhealthy cells in the eye, are primarily driving the uveal melanoma market. In addition to this, the increasing prevalence of numerous associated risk factors, such as advancing age, certain inherited skin disorders, exposure to ultraviolet light, etc., is also augmenting the market growth. Furthermore, the widespread adoption of immune checkpoint inhibitors that target and destroy gp100-expressing uveal melanoma tumor cells is creating a positive outlook for the market. Additionally, the escalating demand for proton therapy, which allows the delivery of potent radiation doses to the tumor with pinpoint accuracy while sparing surrounding healthy tissues, is acting as another significant growth-inducing factor. The therapy aids in preserving the patient's vision and lowers the risk of long-term side effects. Besides this, the emerging popularity of targeted therapies for gene mutations associated with the ailment, since they can limit the growth of cancerous cells and promote overall survival, is further expected to drive the uveal melanoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the uveal melanoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for uveal melanoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the uveal melanoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the uveal melanoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the uveal melanoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current uveal melanoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the uveal melanoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the uveal melanoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the uveal melanoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of uveal melanoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of uveal melanoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of uveal melanoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with uveal melanoma across the seven major markets?
• What is the size of the uveal melanoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of uveal melanoma?
• What will be the growth rate of patients across the seven major markets?
   

Uveal Melanoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for uveal melanoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the uveal melanoma market?
• What are the key regulatory events related to the uveal melanoma market?
• What is the structure of clinical trial landscape by status related to the uveal melanoma market?
• What is the structure of clinical trial landscape by phase related to the uveal melanoma market?
• What is the structure of clinical trial landscape by route of administration related to the uveal melanoma market?